December 8, 2017 8:05pm

Opened up, stayed up yet neutral at the mid-day and closed neutral of our 40 covered companies

 

While the IBB closed up +1.94% after Thursday’s positive +1.53%

Notice the strong got stronger and the weak dived weaker

 

Pre-open indications: 5 hits and 0 miss

Out and about: Fate Therapeutics (FATE) jumps +$0.28 or +6.71% to $4.45 after closing at $4.17 (down -$0.02) on news of the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment.

 

How right does one have to be? You could and should be reading this review of the day’s share pricing activity?

Is the truth so hard to fathom – that’s why my readership has grown exponentially!


Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

Henry’omics:

From the pre-open’s newsletter, “…stock indexes leave investors juggling scattered factors. Numbers and graphs are only a form of shorthand but, do they see the sector behind the numbers? Investors need to understand the potential of anticipation and the distinction of pricing. Fingerprint free algorithms omit any mention of the reasoning behind their selection.”

Reiterating, “… Don’t get too comfortable with a number of those with <equity> upside… from Thursday and Friday!  Remember the fable of Icarus … those who fly too high will get melted by traders. The question is what is sustainable in this volatile world and market.”

Both the Dow and the S&P closed out their third straight weekly advance; though the NASDAQ ended in slightly lower on the week. The gains lifted the Dow and S&P into positive territory for the week. The Dow rose 0.4% for the week while the S&P rose 0.35%. The NASDAQ slipped 0.1% for the week, its second straight weekly decline.

What is there more to say, the oversold came back to life!

But, be carefull next week ...!

 

The advance/decline line scenario of 40 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 23/15 and 2 flat ;

·         The mid-day was neutral with an A/DL of 20/20 and 0 flats;

·         The close was neutral with an A/DL of 19/19 and 1 flat;

 

Pre-open indications: 5 hits and 0 miss

  • bluebird bio (BLUE) closed up +$3.25 – hit;
  • Biostage (BSTG) closed down -$0.0031 – hit;
  • Juno Therapeutics (JUNO) closed up +$1.92 – hit;
  • Regenxbio (RGNX) closed up +$1.45 – hit;
  • VistaGen (VTGN) closed down -$0.23 – hit;

 

Out and about:

Fate Therapeutics (FATE) first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment.

The clinical trial is intended to evaluate the safety and determine the maximum dose of FATE-NK100, FATE’s first-in-class, donor-derived adaptive memory natural killer (NK) cell cancer therapy, as a monotherapy when administered intraperitoneally in the outpatient setting.

A clinical assessment of patients with ovarian cancer has previously shown that endogenous NK cells within the peritoneal fluid exhibit an altered phenotype with reduced cytolytic function.

The APOLLO study is an open-label, accelerated dose-escalation, P1 clinical trial of FATE-NK100 in subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer. Up to three dose levels of FATE-NK100 are intended to be assessed to evaluate safety and determine the maximum dose. Other endpoints to be evaluated include objective response rate at 28 days, and progression-free and overall survival at six months. Subjects with stable disease or better at Day 28 following infusion may be considered for retreatment with FATE-NK100.

 

 

MY working trend lines or indications:

The greatest volume to the downside:  VTGN, CUR, RENE.L, SGMO and ONVO

Upside volume was weighted to:  JUNO, VSTM, NWBO, IMUC and VCEL

Biggest $ downside: SGMO (-$0.30), AXGN (-$0.25), CUR (-$0.24), VTGN (-$0.23) and VCEL (-$0.175)

Largest $ upside:  BLUE (+$3.25), ONCE (+$2.82), JUNO (+$1.92), RGNX (+1.45) and QURE (+$0.80)

Flat:  OSIR and BTX

 

 

Daily analytics:

U.S. stocks rose on Friday, with both the Dow and the S&P 500 ending at records after the November jobs report came in much stronger than expected, underlining the economy’s strong fundamentals.

·         The Dow rose 117.68 points, or 0.5%, to 24,329.16.

·         The S&P 500 added 0.6% to 2,651.50, a gain of 14.52 points.

·         The NASDAQ rose 27.24 points, or 0.4%, to 6,840.08. The finish left the NASDAQ about 1% point from its own record close.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Friday traded at 9.58, down -5.71% …

  • Thursday traded at 10.22, down -7.26% after Wednesday traded at 11.02, down -2.74%, Tuesday traded at 11.33, down -3%, Monday traded at 11.68, up +2.19% and last Friday traded at 11.43, up +1.33% 2% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Friday was up +0.10%

·         Thursday +0.69%

·         Wednesday -0.48%

·         Tuesday -1%

·         Monday -0.39%

·         Last Friday -0.66%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Friday was up +1.94%

·         Thursday +1.53%

·         Wednesday -0.73%

·         Tuesday -0.67%

·         Monday -1.58%

·         Last Friday +0.42%

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Friday’s decliners ranged from -0.48% <FATE -$0.02> to -11.33% <VTGN -$0.23> in 19 equities;

·         Wednesday’s decliners ranged from -0.57% <BLFS -$0.03> to -34.95% <CUR -$1.08> in 29 equities;

·         Tuesday’s decliners ranged from -0.51% <HSGX -$0.01> to -19.23% <FCSC -$0.25> in 21 equities;

·         Monday’s decliners ranged from -0.34% <KOOL -$0.01> to -8.67% <NWBO -$0.0247> in 32 equities;

·         Last Friday’s decliners ranged from -0.09% <MDXG -$0.01> to -6.16% <FCSC -$0.09> in 23 equities;

Versus

 

… Look at the percentage’s (%) and spreads …

·         Friday’s gainers ranged from +0.69% <CLLS +$0.17> to +9.07% <VSTM +$0.36> in 19 equities;

·         Thursday’s gainers ranged from +0.54% <ATHX +$0.01> to +13.47% <QURE +$2.02> in 24 equities;

·         Wednesday’s gainers ranged from +0.65% <AGTC +0.03> to +93.55% <VTGN +$0.87> in 7 equities;

·         Tuesday’s gainers ranged from +0.13% <QURE +$0.02> to +175.89% <CUR +$1.97> in 18 equities;

·         Monday’s gainers ranged from +0.35% <MDXG +$0.04> to +7.78% <VCEL +$0.35> in 7 equities;

·         Last Friday’s gainers ranged from +0.51% <ATHX +$0.01> to +11.46% <BSTG +$0.01> in 16 equities;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.